Drug intelligence / Profile preview

tenapanor + cefadroxil

Development stage: Unknown
Lead developer: Ardelyx
Administration: Oral

Overview

This is not a fixed-dose combination product but represents two separate drugs that were studied together for potential drug-drug interactions. Tenapanor is an inhibitor of gastrointestinal Na+/H+ exchanger NHE3 being evaluated for constipation-predominant irritable bowel syndrome and hyperphosphataemia in chronic kidney disease patients on dialysis. Cefadroxil is a first-generation cephalosporin antibiotic used to treat bacterial infections. A phase 1 study found that tenapanor does not have a clinically relevant impact on the activity of the H+-coupled peptide transporter PepT1, which transports cefadroxil.

Targets

NHE3 (Sodium/hydrogen exchanger 3)

Beyond the preview

Go deeper on tenapanor + cefadroxil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tenapanor + cefadroxil.

Explore the full profile